Traditional screening methods in the field of liver cancer prevention and treatment face numerous challenges. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, the CLiMB trial, led by Professor Richard Van Etten, Director of the UCI Chao Family Comprehensive Cancer Center in the United States, achieved significant results in the early diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients using the innovative HelioLiver Dx testing technology. This research was recognized as a breakthrough and was presented orally (Abstract No. LBO-006). HelioLiver Dx testing technology, which detects multiple epigenetic methylation markers on circulating cell-free DNA (cfDNA) and combines the analysis of various protein markers, successfully overcomes the limitations of ultrasound screening in terms of popularity and sensitivity. The study results show that HelioLiver Dx testing significantly surpasses ultrasound in sensitivity, especially in detecting small liver lesions less than 2 cm. We had an in-depth interview with Professor Van Etten and present the content for our readers.

At the recently concluded European Association for the Study of the Liver (EASL) annual meeting, Professor Frank Tacke from Charité—Universitätsmedizin Berlin presented a special report on the newly released "Clinical Practice Guidelines for the Management of Metabolic Associated Fatty Liver Disease" by EASL, the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO). This guideline covers the latest recommendations from the use of non-invasive diagnostic tools to treatment strategies, emphasizing the importance of managing obesity and diabetes and the need for multidisciplinary collaboration in the management of metabolic associated fatty liver disease. At the conference, Hepatology Digest invited Professor Frank Tacke to provide an authoritative interpretation of the guideline. Professor Tacke stated that this guideline is not only a significant achievement in the field of hepatology but also a major update to the global medical community's diagnostic and treatment plans for MAFLD patients. It places a stronger emphasis on practicality and operability in clinical practice, ensuring better health outcomes for MAFLD patients.

Traditional screening methods in the field of liver cancer prevention and treatment face numerous challenges. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, the CLiMB trial, led by Professor Richard Van Etten, Director of the UCI Chao Family Comprehensive Cancer Center in the United States, achieved significant results in the early diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients using the innovative HelioLiver Dx testing technology. This research was recognized as a breakthrough and was presented orally (Abstract No. LBO-006). HelioLiver Dx testing technology, which detects multiple epigenetic methylation markers on circulating cell-free DNA (cfDNA) and combines the analysis of various protein markers, successfully overcomes the limitations of ultrasound screening in terms of popularity and sensitivity. The study results show that HelioLiver Dx testing significantly surpasses ultrasound in sensitivity, especially in detecting small liver lesions less than 2 cm. We had an in-depth interview with Professor Van Etten and present the content for our readers.